GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ViewRay Inc (OTCPK:VRAYQ) » Definitions » Altman Z-Score

ViewRay (ViewRay) Altman Z-Score : -6.12 (As of Apr. 28, 2024)


View and export this data going back to 2014. Start your Free Trial

What is ViewRay Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

ViewRay has a Altman Z-Score of -6.12, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for ViewRay's Altman Z-Score or its related term are showing as below:


ViewRay Altman Z-Score Historical Data

The historical data trend for ViewRay's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ViewRay Altman Z-Score Chart

ViewRay Annual Data
Trend Nov13 Nov14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.27 0.73 -1.10 0.60 -2.06

ViewRay Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.98 -2.35 -2.18 -2.06 -3.98

Competitive Comparison of ViewRay's Altman Z-Score

For the Medical Devices subindustry, ViewRay's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ViewRay's Altman Z-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ViewRay's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where ViewRay's Altman Z-Score falls into.



ViewRay Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

ViewRay's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.1149+1.4*-3.7456+3.3*-0.4452+0.6*0+1.0*0.454
=-6.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2023:
Total Assets was $233.2 Mil.
Total Current Assets was $193.6 Mil.
Total Current Liabilities was $166.8 Mil.
Retained Earnings was $-873.3 Mil.
Pre-Tax Income was -28.859 + -27.816 + -26.107 + -27.633 = $-110.4 Mil.
Interest Expense was -2.626 + -2.292 + -1.509 + -0.192 = $-6.6 Mil.
Revenue was 22.534 + 34.691 + 26.49 + 22.149 = $105.9 Mil.
Market Cap (Today) was $0.0 Mil.
Total Liabilities was $177.9 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(193.567 - 166.766)/233.159
=0.1149

X2=Retained Earnings/Total Assets
=-873.321/233.159
=-3.7456

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-110.415 - -6.619)/233.159
=-0.4452

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=0.002/177.902
=0

X5=Revenue/Total Assets
=105.864/233.159
=0.454

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

ViewRay has a Altman Z-Score of -6.12 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


ViewRay  (OTCPK:VRAYQ) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


ViewRay Altman Z-Score Related Terms

Thank you for viewing the detailed overview of ViewRay's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


ViewRay (ViewRay) Business Description

Traded in Other Exchanges
N/A
Address
1099 18th Street, Suite 3000, Denver, CO, USA, 80202
ViewRay Inc is a radiation therapy and imaging technology company. It designs, manufactures, and markets radiation therapy systems that provide real-time imaging during radiation treatment. Its product portfolio encompasses The MRIdian linac system, The MRIdian system, the Monte Carlo treatment planning system, etc. The company holds the license for its combination of MRI and radiation therapy technologies. Geographically, it derives a majority of its revenue from the United States.
Executives
Karen Prange director 1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316
B Kristine Johnson director 366 FERNDALE RD S, WAYZATA MN 55391
Sanket Shah officer: SVP, General Counsel C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Farhad Fred Ebrahimi 10 percent owner 191 UNIVERSITY BLVD., #246, DENVER CO 80206
Caley Castelein director THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
Paul Jr Ziegler officer: Chief Commercial Officer C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Scott William Drake director, officer: President and CEO 9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Adam Andrew Podbelski officer: SVP, Customer Services C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Jacob Edward Signoriello officer: Chief Financial Officer C/O VIEWRAY, INC., 1099 18TH STREET, SUITE 3000, DENVER CO 80202
James F. Dempsey director, officer: Chief Scientific Officer C/O VIEWRAY INCORPORATED, 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Burke William P. Mr. officer: Chief Financial Officer HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Susan C Schnabel director C/O CREDIT SUISSE FIRST BOSTON, 11 MADISON AVE, NEW YORK NY 10010
Brian K Roberts director DIGITAS INC.,, 800 BOYLSTON STREET, BOSTON MA 02199
Zachary William Stassen officer: Chief Financial Officer C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Daniel Jeffrey Moore director 100 CYBERONICS BVLD, HOUSTON TX 77058